The BAFF- and APRIL-targeted therapies market is experiencing steady growth driven by the rising prevalence of autoimmune diseases such as systemic lupus erythematosus (SLE), IgA nephropathy, and ...
Patients with SLE respond differentially to rituximab according to their levels of antibodies to double-stranded DNA (anti-dsDNA antibody) levels, the duration of B-cell depletion, and the type of B ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback